In this episode, we spotlight Forum Discussion 01 from the AD/PD™ 2026 International Conference: "Biomarkers to Benefit: Accelerating Translation of Multi-Modal Biomarkers into Disease-Modifying Therapies," held on March 18, 2026.
The discussion was moderated by Prof. Oskar Hansson (Sweden) and Prof. Melissa E. Murray (USA), with expert contributions from Dr. Kanta Horie (USA), Prof. Charlotte E. Teunissen (Netherlands), Prof. Sid O'Bryant (USA), Dr. Tobias Bittner (Switzerland), and Dr. Jorge M. Marques Signes (USA).
Key highlights from this session include:
• The panel's "wish list" of missing biomarkers, from robust tools to identify presymptomatic individuals for prevention trials to synaptic markers that capture neuronal function rather than pathology alone
• The promise and complexity of multi-modal biomarkers combining proteins, RNA, lipids and exosomes, and the risk that composite models become fragile if one component is noisy
• The current role of plasma p-tau217 as a triage tool, the challenge of the 10–20% of patients in the intermediate zone, and regional differences in confirmatory testing with CSF or PET
• The need to validate biomarkers in diverse, representative populations for precision medicine to work in practice
• The search for fluid markers to predict and monitor ARIA, and why current candidates such as neurofilament light do not yet show changes large enough to replace MRI
• Why biomarker improvements in anti-amyloid trials have not always translated into clinical benefit, and the need for more pathology-specific markers, since p-tau217 reflects a mix of amyloid, tau and neurodegeneration
• Co-pathology as the norm in older patients, the difficulty of measuring alpha-synuclein in blood due to peripheral sources, and emerging candidates such as TDP-43 cryptic peptides and CSF markers of microglial states
• Strategies to address false positives in screening, including sequential testing, cognitive pre-screening and AI-supported interpretation, alongside a debate on the analytical robustness of Aβ42/40 ratios
The forum highlighted that biomarkers have already transformed how neurodegenerative diseases are diagnosed and studied, but that translating them into tools that reliably guide treatment requires greater specificity, standardization and validation across diverse populations. The panel emphasized that in real-world care, biomarker results must be interpreted in clinical context, with the physician remaining central to decision-making.
This episode is particularly relevant for neurologists, biomarker researchers, clinical trialists, translational scientists, laboratory and diagnostics professionals, primary care stakeholders, biotech and pharma professionals, and regulators.
This podcast was created using AI to provide a concise and insightful summary of an AD/PD™ 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to consult official conference materials for detailed information.
The AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders took place March 17–21, 2026, in Copenhagen, Denmark.
🔗 https://adpd.kenes.com